Altered ovarian function and cardiovascular risk factors in valproate-treated women - 03/09/11

Doi : 10.1016/S0002-9343(01)00806-3

Jouko I.T Isojärvi, MD, PhD ^⁎,^a, Erik Taubøll, MD, PhD ^e, Arto J Pakarinen, MD, PhD ^b, Johan van Parys, MD, PhD ^g, Johanna Rättyä, MD ^a, Hanne Flinstad Harbo, MD ^e, Per O Dale, MD, PhD ^f, B.C.J.M Fauser, MD ^h, Leif Gjerstad, MD, PhD ^e, Riitta Koivunen, MD ^d, Mikael Knip, MD, PhD ^c, Juha S Tapanainen, MD, PhD ^d
^a Neurology (JITI, JR), University of Oulu, Oulu, Finland
^b Department of Clinical Chemistry (AJP), University of Oulu, Oulu, Finland
^c Department of Pediatrics (MK), University of Oulu, Oulu, Finland
^d Department of Obstetrics and Gynecology (RK, JST), University of Oulu, Oulu, Finland
^e Neurology (ET, HFH, LG), National Hospital, Oslo, Norway
^f Department of Obstetrics and Gynecology (POD), National Hospital, Oslo, Norway
^g Epilepsy Center Heemstede (JVP) Rotterdam, the Netherlands
^h Department of Obstetrics and Gynecology (BCJMF), Academic Hospital Dijkzigt, Rotterdam, the Netherlands

^*Requests for reprints should be addressed to Jouko I. T. Isojärvi, MD, PhD, Department of Neurology, University of Oulu, FIN-90220 Oulu, Finland

Abstract

Purpose

Polycystic ovaries and menstrual disturbances seem to be common among women taking valproate for epilepsy. The purpose of the present study was to assess the frequency of valproate-related metabolic and endocrine disorders in different groups of women with epilepsy.

Subjects and methods

Seventy-two women with epilepsy and 52 control subjects from centers in three European countries (Finland, Norway, and the Netherlands) participated in the study. Thirty-seven of the women with epilepsy were taking valproate monotherapy and 35 carbamazepine monotherapy.

Results

The frequency of polycystic ovaries or hyperandrogenism, or both, among valproate-treated women with epilepsy was 70% (26 of 37) compared with 19% (10 of 52) among control subjects (P <0.001). They were found in 79% (11 of 14) of obese and 65% (15 of 23) of lean women on valproate, and in 20% (7 of 35) of carbamazepine-treated women. The obese valproate-treated women with polycystic ovaries or hyperandrogenism, or both, had hyperinsulinemia and associated unfavorable changes in serum lipid levels consistent with insulin resistance.

Conclusions

Polycystic ovaries and related hyperandrogenism are frequently encountered in both obese and lean women taking valproate for epilepsy. The use of valproate is associated with risk factors for cardiovascular disease in obese women.

Le texte complet de cet article est disponible en PDF.

Plan

Biochemical measurements

Discussion

☆	Supported by grants from the Sigfrid Jusélius Foundation and the Academy of Finland. Preparation of the manuscript was financially supported through a research contract with Glaxo Wellcome Finland Oy.

Export

Vol 111 - N° 4

P. 290-296 - septembre 2001 Retour au numéro

Article précédent

Comparison of the effects of ketoprofen on platelet function in the presence and absence of aspirin
Rodica M Van Solingen, Elliot D Rosenstein, Gabriel Mihailescu, Michele L Drejka, Amita Kalia, Alice J Cohen, Neil Kramer

| Article suivant

Pitfalls in assessing the quality of care for patients with cardiovascular disease
Thomas G. DiSalvo, Sharon-Lise T. Normand, Paul J. Hauptman, Edward Guadagnoli, R.Heather Palmer, Barbara J. McNeil

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Altered ovarian function and cardiovascular risk factors in valproate-treated women - 03/09/11

Abstract

Purpose

Subjects and methods

Results

Conclusions

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL